Haijun Li

The molecular and neurochemical basis of altered intrinsic neural timescales in major depressive disorder: a multimodal imaging-transcriptomic investigation of esketamine and sertraline treatment

BMC Psychiatry August 5, 2026 Xiang Liu, Yuanzhi He, Lifeng Li et al.

Abstract Introduction Major depressive disorder (MDD) is characterized by dysfunction in higher-order cortical regions involved in emotional and cognitive processes; however, its neurobiological basis remains unclear. Pharmacological treatments, including esketamine and sertraline, produce rapid antidepressant effects. We investigated the local intrinsic neural dynamics underlying these...

DOI: 10.1186/s12888-026-08477-0 (opens in new tab)

Esketamine combined with sertraline for brain altered regional homogeneity in patients with major depressive disorder: A preliminary study.

Brain Research Bulletin November 13, 2025 Xiang Liu, Ziyi Hua, Yongqiang Shu et al. 1 citation

This study aims to explore the relationship between the antidepressant effects of drugs (esketamine combined with sertraline) and brain function changes in patients with major depressive disorder. A total of 27 patients with major depressive disorder (MDD) and 27 healthy individuals were included in the study. All MDD patients received a 2-week course of intravenous esketamine infusion (0.25...

DOI: 10.1016/j.brainresbull.2025.111637 (opens in new tab) Full text (opens in new tab) Esketamine Mdd Major depressive disorder Antidepressants +15

Changes in dynamic and static functional connectivity in amygdala subregions in major depressive disorder treated with esketamine in and sertraline: A pilot study.

Journal of Affective Disorders September 1, 2025 Xianghong Liu, Lifeng Li, Haijun Li et al.

INTRODUCTION Dysfunction in amygdala networks has been implicated in major depressive disorder (MDD). Pharmacological treatments, such as esketamine and sertraline, are believed to exert their antidepressant effects by modulating amygdalar activity. This study aimed to investigate the relationship between changes in dynamic functional connectivity (dFC) within amygdala subregions and treatment...

DOI: 10.1016/j.jad.2025.120156 (opens in new tab)

Antidepressant effects of esketamine are associated with functional connectivity in the hippocampal subregion: A resting state magnetic resonance study.

Neuroscience July 8, 2025 Xiang Liu, Yumeng Liu, Jun Tu et al. 2 citations

We aimed to investigate the relationship between changes in resting-state functional connectivity in a subregion of the hippocampus and the antidepressant effects of esketamine as well as to identify potential neuroimaging markers of the treatment outcomes. Twenty-nine patients with major depressive disorder (MDD) received six intravenous infusions of esketamine. All patients completed the...

DOI: 10.1016/j.neuroscience.2025.07.016 (opens in new tab) Full text (opens in new tab) Esketamine Major depressive disorder Mdd Functional connection +14

Effect of continuous esketamine infusion on brain white matter microstructure in patients with major depression: A diffusion tensor imaging study.

Journal of Affective Disorders March 1, 2025 Xiang Liu, Zhipeng Wei, Lifeng Li et al. 12 citations

Esketamine has demonstrated acute antidepressant effects in patients with major depressive disorder (MDD). This study investigated whether these effects associate with reversible white matter fiber integrity recovery using diffusion imaging. Twenty patients with MDD and 20 healthy controls received 2-week esketamine treatment. Patients received 0.25 mg/kg intravenous esketamine. Emotional and...

DOI: 10.1016/j.jad.2024.12.002 (opens in new tab) Full text (opens in new tab) Major depressive disorder Mdd Antidepressants antidepressant medication Depression medication +5